Numerous biotech companies are rushing to go public in 2024, sparking an IPO wave. New entrants are set to emerge across various platforms, including the Emerging Stock Market, Over-the-Counter Market, and the main stock exchange, covering a wide range of sectors such as new drugs, health products, fertility, and long-term care. Among them, the well-known health brand Daiken Biomedical is set to list on the Emerging Stock Market at an offering price of NT$68 per share. The company surpassed NT$1 billion in revenue last year, reporting self-assessed revenue of NT$1.19 billion, a year-on-year increase of 34.6%, with a net profit of NT$160 million, translating to earnings per share of NT$10.32. The listing is expected to take place on October 28.
This wave of new biotech entrants includes Bonraybio, which focuses on male infertility and plans to list on the Innovation Board, while BRIM Biotechnology, which specializes in eye medications, has already passed its listing application. Qing Song Health, involved in long-term care services, has submitted its application for stock listing. NaviFUS and WeLeader Biomedical have filed for Over-the-Counter listings. Additionally, Daiken Biomedical is set to debut on the Emerging Stock Market on October 28, and Anya Biopharm will join the ranks of emerging biotech stocks on October 25.
Bonraybio primarily generates revenue from bio-detection instruments and medical consumables, providing comprehensive solutions for male infertility within the global reproductive healthcare industry. The company aims to simplify and standardize complex medical testing procedures through continuous innovation in reproductive healthcare testing products. Its full range of products includes the sperm quality analysis instrument (X1PRO) paired with specialized sperm test strips (CS1), which generate conventional sperm testing data through AI calculations, marketed globally under its own brand.
WeLeader Biomedical focuses on the development of medical devices for in vitro diagnostics and precision medicine in the preventive healthcare market. The company primarily acts as a distributor for Roche medical diagnostic equipment and related services while extending its offerings to downstream clients by providing digital information platforms to medical laboratories and healthcare institutions across Taiwan. Through its subsidiary, Youpin Biomedical Information Team, WeLeader develops medical information service platforms and apps in response to the informational service needs of downstream medical laboratories and institutions, offering professional digital healthcare information services.
Daiken Biomedical is primarily engaged in the research, sales, and brand management of health food products. Its current product line includes fish oil, lutein, maca, and bitter melon peptide cinnamon capsules. As of the end of August this year, Daiken has 30 products available for sale. The company also plans to further develop existing products, introducing an affordable Australian brand and a local Japanese brand in addition to its current offerings. This strategy aims to cater to diverse customer groups, expand into various market segments, and achieve optimal economic benefits by increasing market share.
Resource (mandarin): 生醫股IPO潮！大研生醫、奧孟亞登興櫃
